Compare VTOL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | RCUS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | VTOL | RCUS |
|---|---|---|
| Price | $37.08 | $21.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.38 |
| AVG Volume (30 Days) | 172.7K | ★ 2.0M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 148.42 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | ★ $1,466,774,000.00 | $240,000,000.00 |
| Revenue This Year | $8.09 | N/A |
| Revenue Next Year | $8.76 | N/A |
| P/E Ratio | $7.83 | ★ N/A |
| Revenue Growth | ★ 2.95 | N/A |
| 52 Week Low | $25.11 | $6.50 |
| 52 Week High | $42.89 | $26.40 |
| Indicator | VTOL | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 43.57 |
| Support Level | $35.90 | $24.75 |
| Resistance Level | $37.91 | $26.10 |
| Average True Range (ATR) | 1.03 | 1.50 |
| MACD | 0.04 | -0.41 |
| Stochastic Oscillator | 51.93 | 21.97 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, India, Ireland, the Kingdom of Saudi Arabia, Mexico, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the UK, and the U.S. offshore energy customers use services to transport personnel to, from and between offshore energy installations.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.